Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

POC (point-of-care) bladder cancer test proves accurate:

This article was originally published in Clinica

Executive Summary

Matritech's point-of-care (POC) test for bladder cancer is as accurate as the company's FDA-approved laboratory-based version of the test, according to a study of 96 individuals. The overall concordance between the POC NMP22 BladderChek test and Matritech's current NMP22 microplate format test was 95%, reports the Newton, Massachusetts firm. BladderChek works much like a home pregnancy test and can produce results while the patient is in the doctor's office. Current tests performed in a central laboratory take two to three days to deliver results, said the company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel